• Something wrong with this record ?

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

SP. Aix, TE. Ciuleanu, A. Navarro, S. Cousin, L. Bonanno, EF. Smit, A. Chiappori, ME. Olmedo, I. Horvath, C. Grohé, AF. Farago, JA. López-Vilariño, M. Cullell-Young, A. Nieto, N. Vasco, J. Gómez, C. Kahatt, A. Zeaiter, E. Carcereny, J. Roubec, K....

. 2023 ; 11 (1) : 74-86. [pub] 20221014

Language English Country England, Great Britain

Document type Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article

BACKGROUND: Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin as second-line treatment for SCLC. METHODS: In this phase 3, open-label, randomised study, adult patients aged 18 years or older with SCLC who relapsed after platinum-based chemotherapy were recruited from 135 hospitals across North America, South America, Europe, and the Middle East. Patients were randomly assigned (1:1) centrally by dynamic allocation to intravenous lurbinectedin 2·0 mg/m2 plus doxorubicin 40·0 mg/m2 administered on day 1 of 21-day cycles or physician's choice of control therapy (intravenous topotecan 1·5 mg/m2 on days 1-5 of 21-day cycles; or intravenous cyclophosphamide 1000 mg/m2, doxorubicin 45·0 mg/m2, and vincristine 2·0 mg on day 1 of 21-day cycles [CAV]) administered until disease progression or unacceptable toxicity. Primary granulocyte-colony stimulating factor prophylaxis was mandatory in both treatment groups. Neither patients nor clinicians were masked to treatment allocation, but the independent review committee, which assessed outcomes, was masked to patients' treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02566993, and with EudraCT, 2015-001641-89, and is complete. FINDINGS: Between Aug 30, 2016, and Aug 20, 2018, 613 patients were randomly assigned to lurbinectedin plus doxorubicin (n=307) or control (topotecan, n=127; CAV, n=179) and comprised the intention-to-treat population; safety endpoints were assessed in patients who had received any partial or complete study treatment infusions (lurbinectedin plus doxorubicin, n=303; control, n=289). After a median follow-up of 24·1 months (95% CI 21·7-26·3), 303 patients in the lurbinectedin plus doxorubicin group and 289 patients in the control group had discontinued study treatment; progressive disease was the most common reason for discontinuation (213 [70%] patients in the lurbinectedin plus doxorubicin group vs 152 [53%] in the control group). Median overall survival was 8·6 months (95% CI 7·1-9·4) in the lurbinectedin plus doxorubicin group versus 7·6 months (6·6-8·2) in the control group (stratified log-rank p=0·90; hazard ratio 0·97 [95% CI 0·82-1·15], p=0·70). 12 patients died because of treatment-related adverse events: two (<1%) of 303 in the lurbinectedin plus doxorubicin group and ten (3%) of 289 in the control group. 296 (98%) of 303 patients in the lurbinectedin plus doxorubicin group had treatment-emergent adverse events compared with 284 (98%) of 289 patients in the control group; treatment-related adverse events occurred in 268 (88%) patients in the lurbinectedin plus doxorubicin group and 266 (92%) patients in the control group. Grade 3 or worse haematological adverse events were less frequent in the lurbinectedin plus doxorubicin group than the control group (anaemia, 57 [19%] of 302 patients in the lurbinectedin plus doxorubicin group vs 110 [38%] of 288 in the control group; neutropenia, 112 [37%] vs 200 [69%]; thrombocytopenia, 42 [14%] vs 90 [31%]). The frequency of treatment-related adverse events leading to treatment discontinuation was lower in the lurbinectedin plus doxorubicin group than in the control group (26 [9%] of 303 patients in the lurbinectedin plus doxorubicin group vs 47 [16%] of 289 in the control group). INTERPRETATION: Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control. FUNDING: PharmaMar.

Aristotle University of Thessaloniki Thessaloniki Greece

Asklepios Fachkliniken München Gauting Germany

Badalona Applied Research Group in Oncology and Medical Oncology Department Catalan Institute of Oncology Badalona Germans Trias i Pujol Hospital Barcelona Spain

Ciberonc Madrid Spain

Clatterbridge Cancer Centre NHS Foundation Trust Wirral UK

CNIO H12o Lung Cancer Clinical Research Unit Madrid Spain

Department of Medical Oncology Hospital Universitario 12 de Octubre Madrid Spain

Department of Medical Oncology Hospital Universitario La Fe Valencia Spain

Department of Medical Oncology Institut Bergonié Bordeaux France

Department of Oncology Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca Romania

Department of Respiratory Diseases Evangelische Lungenklinik Berlin Berlin Germany

Department of Thoracic Oncology H Lee Moffitt Cancer Center and Research Institute Tampa FL USA

Department of Thoracic Oncology Netherlands Cancer Institute Amsterdam Netherlands

Harvard Medical School Boston MA USA

Hospital Provincial Reina Sofía Córdoba Spain

Hospital Universitario Fundación Jiménez Diaz Madrid Spain

Hospital Universitario Ramón y Cajal Madrid Spain

Hospital Universitario Virgen del Rocío Seville Spain

Hotel Dieu de France University Hospital Saint Joseph University Beirut Lebanon

Massachusetts General Hospital Cancer Center Boston MA USA

Medical Oncology 2 Istituto Oncologico Veneto Padova Italy

Medical Oncology Department Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology Barcelona Spain

National and Kapodistrian University of Athens Athens Greece

National Koranyi Institute for Pulmonology Budapest Hungary

Nemocnice AGEL Ostrava Vítkovice Ostrava Vítkovice Czech Republic

PharmaMar Madrid Spain

R S McLaughlin Durham Regional Cancer Centre Lakeridge Health Oshawa ON Canada

Thoraxklinik at Heidelberg University Hospital Heidelberg Germany

Universidad Complutense de Madrid Madrid Spain

University Medical Centre Freiburg Freiburg Germany

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032058
003      
CZ-PrNML
005      
20230131151820.0
007      
ta
008      
230120s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2213-2600(22)00309-5 $2 doi
035    __
$a (PubMed)36252599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aix, Santiago Ponce $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
245    10
$a Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial / $c SP. Aix, TE. Ciuleanu, A. Navarro, S. Cousin, L. Bonanno, EF. Smit, A. Chiappori, ME. Olmedo, I. Horvath, C. Grohé, AF. Farago, JA. López-Vilariño, M. Cullell-Young, A. Nieto, N. Vasco, J. Gómez, C. Kahatt, A. Zeaiter, E. Carcereny, J. Roubec, K. Syrigos, G. Lo, I. Barneto, A. Pope, A. Sánchez, J. Kattan, K. Zarogoulidis, CF. Waller, H. Bischoff, O. Juan-Vidal, N. Reinmuth, M. Dómine, L. Paz-Ares
520    9_
$a BACKGROUND: Lurbinectedin is a synthetic marine-derived anticancer agent that acts as a selective inhibitor of oncogenic transcription. Lurbinectedin monotherapy (3·2 mg/m2 every 3 weeks) received accelerated approval from the US Food and Drug Administration on the basis of efficacy in patients with small-cell lung cancer (SCLC) who relapsed after first-line platinum-based chemotherapy. The ATLANTIS trial assessed the efficacy and safety of combination lurbinectedin and the anthracycline doxorubicin as second-line treatment for SCLC. METHODS: In this phase 3, open-label, randomised study, adult patients aged 18 years or older with SCLC who relapsed after platinum-based chemotherapy were recruited from 135 hospitals across North America, South America, Europe, and the Middle East. Patients were randomly assigned (1:1) centrally by dynamic allocation to intravenous lurbinectedin 2·0 mg/m2 plus doxorubicin 40·0 mg/m2 administered on day 1 of 21-day cycles or physician's choice of control therapy (intravenous topotecan 1·5 mg/m2 on days 1-5 of 21-day cycles; or intravenous cyclophosphamide 1000 mg/m2, doxorubicin 45·0 mg/m2, and vincristine 2·0 mg on day 1 of 21-day cycles [CAV]) administered until disease progression or unacceptable toxicity. Primary granulocyte-colony stimulating factor prophylaxis was mandatory in both treatment groups. Neither patients nor clinicians were masked to treatment allocation, but the independent review committee, which assessed outcomes, was masked to patients' treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02566993, and with EudraCT, 2015-001641-89, and is complete. FINDINGS: Between Aug 30, 2016, and Aug 20, 2018, 613 patients were randomly assigned to lurbinectedin plus doxorubicin (n=307) or control (topotecan, n=127; CAV, n=179) and comprised the intention-to-treat population; safety endpoints were assessed in patients who had received any partial or complete study treatment infusions (lurbinectedin plus doxorubicin, n=303; control, n=289). After a median follow-up of 24·1 months (95% CI 21·7-26·3), 303 patients in the lurbinectedin plus doxorubicin group and 289 patients in the control group had discontinued study treatment; progressive disease was the most common reason for discontinuation (213 [70%] patients in the lurbinectedin plus doxorubicin group vs 152 [53%] in the control group). Median overall survival was 8·6 months (95% CI 7·1-9·4) in the lurbinectedin plus doxorubicin group versus 7·6 months (6·6-8·2) in the control group (stratified log-rank p=0·90; hazard ratio 0·97 [95% CI 0·82-1·15], p=0·70). 12 patients died because of treatment-related adverse events: two (<1%) of 303 in the lurbinectedin plus doxorubicin group and ten (3%) of 289 in the control group. 296 (98%) of 303 patients in the lurbinectedin plus doxorubicin group had treatment-emergent adverse events compared with 284 (98%) of 289 patients in the control group; treatment-related adverse events occurred in 268 (88%) patients in the lurbinectedin plus doxorubicin group and 266 (92%) patients in the control group. Grade 3 or worse haematological adverse events were less frequent in the lurbinectedin plus doxorubicin group than the control group (anaemia, 57 [19%] of 302 patients in the lurbinectedin plus doxorubicin group vs 110 [38%] of 288 in the control group; neutropenia, 112 [37%] vs 200 [69%]; thrombocytopenia, 42 [14%] vs 90 [31%]). The frequency of treatment-related adverse events leading to treatment discontinuation was lower in the lurbinectedin plus doxorubicin group than in the control group (26 [9%] of 303 patients in the lurbinectedin plus doxorubicin group vs 47 [16%] of 289 in the control group). INTERPRETATION: Combination therapy with lurbinectedin plus doxorubicin did not improve overall survival versus control in patients with relapsed SCLC. However, lurbinectedin plus doxorubicin showed a favourable haematological safety profile compared with control. FUNDING: PharmaMar.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a topotekan $x terapeutické užití $7 D019772
650    _2
$a doxorubicin $x škodlivé účinky $7 D004317
650    12
$a nádory plic $x etiologie $7 D008175
650    12
$a lékaři $7 D010820
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ciuleanu, Tudor Eliade $u Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca, Romania
700    1_
$a Navarro, Alejandro $u Medical Oncology Department, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
700    1_
$a Cousin, Sophie $u Department of Medical Oncology, Institut Bergonié, Bordeaux, France
700    1_
$a Bonanno, Laura $u Medical Oncology 2, Istituto Oncologico Veneto, Padova, Italy
700    1_
$a Smit, Egbert F $u Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
700    1_
$a Chiappori, Alberto $u Department of Thoracic Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
700    1_
$a Olmedo, Maria Eugenia $u Hospital Universitario Ramón y Cajal, Madrid, Spain
700    1_
$a Horvath, Ildiko $u National Koranyi Institute for Pulmonology, Budapest, Hungary
700    1_
$a Grohé, Christian $u Department of Respiratory Diseases, Evangelische Lungenklinik Berlin, Berlin, Germany
700    1_
$a Farago, Anna F $u Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA
700    1_
$a López-Vilariño, José Antonio $u PharmaMar, Madrid, Spain
700    1_
$a Cullell-Young, Martin $u PharmaMar, Madrid, Spain
700    1_
$a Nieto, Antonio $u PharmaMar, Madrid, Spain
700    1_
$a Vasco, Noelia $u PharmaMar, Madrid, Spain
700    1_
$a Gómez, Javier $u PharmaMar, Madrid, Spain
700    1_
$a Kahatt, Carmen $u PharmaMar, Madrid, Spain
700    1_
$a Zeaiter, Ali $u PharmaMar, Madrid, Spain
700    1_
$a Carcereny, Enric $u Badalona-Applied Research Group in Oncology (B-ARGO) and Medical Oncology Department, Catalan Institute of Oncology Badalona, Germans Trias i Pujol Hospital, Barcelona, Spain
700    1_
$a Roubec, Jaromir $u Nemocnice AGEL Ostrava-Vítkovice, Ostrava-Vítkovice, Czech Republic
700    1_
$a Syrigos, Konstantinos $u National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Lo, Gregory $u R S McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON, Canada
700    1_
$a Barneto, Isidoro $u Hospital Provincial Reina Sofía, Córdoba, Spain
700    1_
$a Pope, Anthony $u Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
700    1_
$a Sánchez, Amparo $u Hospital Universitario Virgen del Rocío, Seville, Spain
700    1_
$a Kattan, Joseph $u Hotel-Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon
700    1_
$a Zarogoulidis, Konstantinos $u Aristotle University of Thessaloniki, Thessaloniki, Greece
700    1_
$a Waller, Cornelius F $u University Medical Centre Freiburg, Freiburg, Germany
700    1_
$a Bischoff, Helge $u Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Juan-Vidal, Oscar $u Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
700    1_
$a Reinmuth, Niels $u Asklepios Fachkliniken München, Gauting, Germany
700    1_
$a Dómine, Manuel $u Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain
700    1_
$a Paz-Ares, Luis $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; CNIO-H12o Lung Cancer Clinical Research Unit, Madrid, Spain; Ciberonc, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. Electronic address: lpazaresr@seom.org
773    0_
$w MED00188827 $t The Lancet. Respiratory medicine $x 2213-2619 $g Roč. 11, č. 1 (2023), s. 74-86
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36252599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151816 $b ABA008
999    __
$a ok $b bmc $g 1891060 $s 1183393
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 11 $c 1 $d 74-86 $e 20221014 $i 2213-2619 $m The Lancet Respiratory medicine $n Lancet Respir Med $x MED00188827
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...